Dialysis Access DysfunctionNCT07548814
Evaluation of the 2-year AVF Utilization Rate
An observational study of Dialysis Access Dysfunction and Fistulae, run by University Paul Sabatier of Toulouse at 1 site in France.
Trial summary
Arteriovenous fistulas (AVFs) are the standard for dialysis sessions. However, this usually requires surgery before dialysis can begin. Given this pre-operative approach, the investigators evaluate the two-year utilization rate of AVFs and seek to understand why they are still not used in some cases. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Dialysis Access Dysfunction, Fistulae
- What is being tested?
- AVF creation as indicated by the nephrologist
- Type of treatment
- Surgery or procedure
- How many people
- 1,000 participants
- Where
- 1 siteFrance
- Study dates
- 1 Jan 2018to 1 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients for whom the neprhologist indicated an AVF creation
Who may be able to join
- First AVF creation
Who cannot join
- Minor patient
- AVF already
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation, 2 Years Post-creation, of the AVF Utilization Rate
Arteriovenous fistulas (AVFs) are the standard for dialysis sessions. However, this usually requires surgery before dialysis can begin. Given this pre-operative approach, the investigators evaluate the two-year utilization rate of AVFs and seek to understand why they are still not used in some cases.
- Conditions
- Dialysis Access Dysfunction, Fistulae
- Being tested
- AVF creation as indicated by the nephrologist
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AVF creation as indicated by the nephrologistProcedure or surgery
AVF are creation in the OR when asked by the nephrologist team
| Study group | Role | What they receive |
|---|---|---|
| AVF creation non dialysed patient | Not described Receives: Procedure: AVF creation as indicated by the nephrologist |
What is being measured
The primary outcome is the main question the study is designed to answer.
AVF utilisation
AVF puncture
Measured: through study completion, an average of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Apr 2026
- Study start1 Jan 2018
- Primary completion1 Jan 2026
- Study completion1 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dialysis Access DysfunctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 1,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Paul Sabatier of Toulouse
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Aurélien Hostalrich, University Paul Sabatier of Toulouse
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07548814
- Sponsor's protocol ID
- UTIFAV
- Status last verified
- Jan 2026
- First submitted
- 14 Apr 2026
- Last updated
- 23 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation, 2 Years Post-creation, of the AVF Utilization Rate
- ClinicalTrials.gov ID
- NCT07548814
- Acronym / sponsor ID
- UTIFAV
- Conditions
- Dialysis Access Dysfunction, Fistulae
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- University Paul Sabatier of ToulouseUniversity, hospital or other
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- 1 Jan 2026 (actual)
- Study completion
- 1 Dec 2026 (estimated)
- First posted
- 23 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Arteriovenous fistulas (AVFs) are the standard for dialysis sessions. However, this usually requires surgery before dialysis can begin. Given this pre-operative approach, the investigators evaluate the two-year utilization rate of AVFs and seek to understand why they are still not used in some cases.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| AVF creation non dialysed patient | – | Procedure: AVF creation as indicated by the nephrologist |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients for whom the neprhologist indicated an AVF creation
Key inclusion criteria (1 listed)
- First AVF creation
Key exclusion criteria (2 listed)
- Minor patient
- AVF already
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AVF creation as indicated by the nephrologistAVF are creation in the OR when asked by the nephrologist team | Procedure or surgery | AVF creation non dialysed patient |
Primary outcome
AVF utilisation
Time frame: through study completion, an average of 2 years
AVF puncture
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2026.
- Individual participant dataSharing planned: No
Related trials for Dialysis Access Dysfunction
Not yet recruiting
Impact of a Tunneled Hemodialysis Catheter With Endexo® Technology on Catheter Dysfunction Compared With Historical Catheter Dysfunction Data in Standard Catheters
Haemodialysis, Haemodialysis Complication
Recruiting
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Chronic Kidney Diseases, End Stage Renal Disease
Active, not recruiting
SelfWrap-Assisted Arteriovenous Fistulas
Chronic Kidney Diseases, Chronic Kidney Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Dialysis Access Dysfunction and Fistulae, run by University Paul Sabatier of Toulouse at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 23 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
AVF utilisation (time frame: through study completion, an average of 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2026.